Lilly drops plan to seek expanded approval for Cymbalta

Eli Lilly and Co. withdrew its request for FDA approval to market its antidepressant Cymbalta for the treatment of chronic pain in the knee and back. The company said it intends to resubmit the application in the first half of next year, after it addresses the agency's concerns about Cymbalta's dosing and efficacy.

View Full Article in:

Reuters · Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA